Insights

Pharmaceutical Industry Insights, Technical Articles and Expert Interviews

Stay informed with practical insights from across the pharmaceutical outsourcing landscape.

Our News & Insights section features technical articles, expert commentary and interviews with service providers from the Pharma Services Hub network. Content covers pharmaceutical development, manufacturing, quality, regulatory affairs, analytical sciences, outsourcing strategy and emerging industry trends.

Whether you are evaluating service providers, developing a new product or seeking specialist knowledge, these resources are designed to support informed decision-making and help you navigate complex development challenges and service provider selection.

Radiopharmaceutical Development: Key CMC and Regulatory Considerations for First-Time Sponsors. Paul Faulds. Regulink

Radiopharmaceuticals are becoming increasingly important in modern drug development, supporting precision diagnosis, patient selection, targeted therapy, and personalised treatment pathways. We speak with Paul Faulds, a consultant at Regulink and a specialist in radiopharmaceutical CMC and regulatory strategy to address the critical considerations sponsors should understand before initiating a radiopharmaceutical development programme.

Selecting the Right Partner for Complex Sterile Advanced Therapies

Pharma Services Hub spoke with Simon Phillips, Head of Sterile Manufacturing at Nova Laboratories to discuss the key factors that outsourcing companies should consider when selecting a sterile manufacturing partner and how technical innovation, sterility assurance and long-term collaboration underpin project success.

Main article image showing management team discussing investor strategy

Investor Readiness in Biotech: Why CMC, DMPK and Clinical Pharmacology Data Can Make or Break the Investment Case

As part of our consultancy insights series, Marcel de Matas, Chief Business Officer and Founder at Seda discusses the importance of investor readiness to help companies assess how well their development story, CMC package, and clinical pharmacology strategy will stand up to scrutiny.

Biopharmaceutics Assessment: Identifying the Correct Approach for In Vitro Studies

As part of our small molecule insights series we review the growing importance of biopharmaceutics assessment with Dr. Mark McAllister, Chief Scientific Officer of Biowaived (UK). Mark shares his perspectives on how to identify the correct approach, avoid common pitfalls, and leverage in vitro testing to accelerate successful outcomes in drug product design and clinical exposure/efficacy.

Contract Research Organisation Selection - Important Considerations

As part of our discovery and development series Dr Shailendra Singh CEO at Cellomatics Biosciences provides his insights into the important considerations which must be made when identifying and building partnerships with Contract Research Organisations.

Developability Assessment, Formulation Screening, and Enabled Technologies to Advance Challenging Molecules Through Clinical Development

As part of our small molecule insights series, we review the essential aspects to assess developability and selection of the correct technology to support drug product development.

image to capsules inside a larger capsule

Essential aspects to consider when transitioning a lead candidate from Drug Substance to Drug Product using enabling formulation strategies

As part of our small molecule insights interview series, we review the Essential aspects to consider when transitioning a lead candidate from drug substance (DS) to drug product (DP) using enabling formulation strategies.

Accelerating Molecules to Medicines: The importance of End to End CMC Service Provision

As part of our technical insights series, we asked Tara Hope (Director - Business Development, Drug Product at Pharmaron) what are the key factors to consider when selecting organisations to support end to end CMC services.

Why Drug Solubility Matters: Understanding Its Central Role in Bioavailability and Successful DS/DP Development

As part of our small technical insights series Terry Ernest and Jonathan Loughrey explain Why Drug Solubility Matters and why choosing the right development partner is critical for project success.